

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM826452

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MIDCAP FUNDING IV TRUST		07/20/2023	Statutory Trust: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Sight Sciences, Inc.		
<b>Street Address:</b>	4040 Campbell Avenue, Suite 100		
<b>City:</b>	Menlo Park		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94025		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 8</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4893267	SIGHT SCIENCES	
<b>Registration Number:</b>	4704448	TRAB	
<b>Registration Number:</b>	5133983	TEARCARE	
<b>Registration Number:</b>	4956395	VISCO360	
<b>Registration Number:</b>	5326183	ILID	
<b>Serial Number:</b>	87549559	OMNI	
<b>Serial Number:</b>	88253594	TEARCARE CLEARANCE ASSISTANT	
<b>Serial Number:</b>	88253808	TEARCARE SMARTLIDS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7036106200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	7036106100		
<b>Email:</b>	dctrademark@hoganlovells.com		
<b>Correspondent Name:</b>	Greta D. Feldman of Hogan Lovells US LLP		
<b>Address Line 1:</b>	8350 Broad St. 17th Floor		
<b>Address Line 4:</b>	Tysons,, VIRGINIA 22102		
<b>NAME OF SUBMITTER:</b>	Greta D. Feldman of Hogan Lovells US LLP		
<b>SIGNATURE:</b>	/Greta D. Feldman/		

CH \$215.00 4893267

<b>DATE SIGNED:</b>	07/24/2023
---------------------	------------

**Total Attachments: 4**

source=MidCap - Sight Science - TM Release and Termination (Revolving)#page1.tif

source=MidCap - Sight Science - TM Release and Termination (Revolving)#page2.tif

source=MidCap - Sight Science - TM Release and Termination (Revolving)#page3.tif

source=MidCap - Sight Science - TM Release and Termination (Revolving)#page4.tif

## RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This Release of Intellectual Property Security Interest, dated as of July 20, 2023, is made by **MIDCAP FUNDING IV TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **SIGHT SCIENCES, INC.**, a Delaware corporation (the “**Grantor**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement (Revolving Loan), dated as of January 25, 2019 (as may have been amended, modified, restated, replaced, reaffirmed or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on January 28, 2019 at Reel/Frame No. 6539/0792 (Trademarks) and on January 28, 2019 at Reel/Frame No. 048149/0230 (Patents), as reaffirmed pursuant to that certain Reaffirmation Agreement and Amendment to Intellectual Property Security Agreement dated as of November 23, 2020, recorded with the United States Patent and Trademark Office on November 25, 2020 at Reel/Frame No. 7115/0683 (Trademarks), and on November 25, 2020 at Reel/Frame No. 054524/0008 (Patents), wherein Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of Grantor’s intellectual property, including those listed on Exhibit A through D thereto;

WHEREAS, the Grantor has requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantor’s sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Intellectual Property Security Interest to be duly executed and delivered by its duly authorized officer as of the date first written above.


**AGENT:**

**MIDCAP FUNDING IV TRUST**

as Agent


By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
\_\_\_\_\_  
Name: Maurice Amsellem  
Title: Authorized Signatory

Schedule B

Trademarks

<u>Mark/Serial Number/Registration Number/Listed Owner</u>	<u>Country</u>	<u>Class/Goods and Services</u>	<u>Status</u>
<p>SIGHT SCIENCES &amp; DESIGN Serial No: 85/750,658 Reg. No: 4,893,267</p> <p>Sight Sciences, Inc.</p>  <p>SIGHT SCIENCES</p>	United States of America	<p>Class 05: Pharmaceuticals and diagnostic preparations for the treatment of ophthalmic conditions</p> <p>Class 10: Medical devices for treatment of ophthalmic conditions; drug delivery systems</p>	<p>Registered App Date: 10/10/2012 Reg Date: 01/26/2016</p> <p>Section 8 &amp; 15 Due: 01/26/2022</p>
<p>TRAB Serial No: 85/928,028 Reg. No: 4,704,448</p> <p>Sight Sciences, Inc.</p>	United States of America	Class 10: Surgical instruments for ophthalmological procedures	<p>Registered App Date: 05/09/2013 Reg Date: 03/17/2015</p> <p>Section 8 &amp; 15 Due: 03/17/2021</p>
<p>TEARCARE Serial No: 85/928,463 Reg. No: 5,133,983</p> <p>Sight Sciences, Inc.</p>	United States of America	Class 10: Medical devices for the treatment of ophthalmological conditions	<p>Registered App Date: 05/10/2013 Reg Date: 01/31/2017</p> <p>Section 8 &amp; 15 Due: 01/31/2023</p>
<p>VISCO360 Serial No: 86/212,270 Reg. No: 4,956,395</p> <p>Sight Sciences, Inc.</p>	United States of America	Class 10: Medical devices for treatment of ophthalmic conditions	<p>Registered App Date: 03/05/2014 Reg Date: 05/10/2016</p> <p>Section 8 &amp; 15 Due: 05/10/2022</p>
<p>ILID Serial No: 87/394,901 Reg. No: 5,326,183</p>	United States of America	Class 10: Therapeutic eyelid devices for the treatment of eye	<p>Registered App Date: 03/31/2017</p>

<u>Mark/Serial Number/Registration Number/Registered Owner</u>	<u>Country</u>	<u>Class/Goods and Services</u>	<u>Status</u>
Sight Sciences, Inc.		conditions	Reg Date: 10/31/2017  Section 8 & 15 Due: 10/31/2023
OMNI Serial No: 87/549,559 Reg. No:  Sight Sciences, Inc.	United States of America	Class 10: Medical devices, namely, manual surgical instruments for performing anterior segment surgery in the eye	Allowed - Intent to Use App Date: 07/31/2017 Reg Date:  <b>Statement of Use Due/EOTI: 07/01/2019</b>
TEARCARE CLEARANCE ASSISTANT Serial No: 88/253,594 Reg. No:  Sight Sciences, Inc.	United States of America	Class 10: Medical devices, namely, manual forceps for compression of eyelid glands	Filed - Intent to Use App Date: 01/08/2019 Reg Date:  Application Pending
TEARCARE SMARTLID Serial No: 88/253,808 Reg. No:  Sight Sciences, Inc.	United States of America	Class 10: Medical devices in the nature of therapeutic eyelid devices for the treatment of eye conditions	Filed - Intent to Use App Date: 01/08/2019 Reg Date:  Application Pending